Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Cash & Current Investments (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Cash & Current Investments for 3 consecutive years, with $44.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 139.69% to $44.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.3 million through Dec 2025, up 139.69% year-over-year, with the annual reading at $44.3 million for FY2025, 139.69% up from the prior year.
  • Cash & Current Investments hit $44.3 million in Q4 2025 for Connect Biopharma Holdings, down from $54.7 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $118.3 million in Q4 2023 to a low of $18.5 million in Q4 2024.
  • Historically, Cash & Current Investments has averaged $65.3 million across 3 years, with a median of $63.3 million in 2025.
  • Biggest five-year swings in Cash & Current Investments: tumbled 84.36% in 2024 and later soared 139.69% in 2025.
  • Year by year, Cash & Current Investments stood at $118.3 million in 2023, then crashed by 84.36% to $18.5 million in 2024, then skyrocketed by 139.69% to $44.3 million in 2025.
  • Business Quant data shows Cash & Current Investments for CNTB at $44.3 million in Q4 2025, $54.7 million in Q3 2025, and $71.8 million in Q2 2025.